Janet Woodcock, acting commissioner of the US Food and Drug Administration, has asked federal officials to conduct an investigation of interactions between agency staff and executives at Biogen Inc in the process that led up to the FDA’s approval of Aduhelm (aducanumab) for Alzheimer’s disease on 7 June. A letter was sent to the acting inspector general of the Department of Health and Human Services on 9 July and distributed globally on the same day on Twitter.
